1. Academic Validation
  2. Astragaloside IV alleviates ulcerative colitis via gut microbiota - butyrate metabolism axis to reshape Th17/Treg balance

Astragaloside IV alleviates ulcerative colitis via gut microbiota - butyrate metabolism axis to reshape Th17/Treg balance

  • Int Immunopharmacol. 2026 Feb 15:171:116135. doi: 10.1016/j.intimp.2025.116135.
Youbao Zhong 1 Jing Liu 2 Jiaqi Huang 2 Ji Yu 2 Yazhen Liu 2 Wang Zhuo 3 Youhui Xu 2 Yixi Zhang 2 Zhiyu Zhou 4 Liling Chen 5 Qiuping Xiao 6 Duanyong Liu 7
Affiliations

Affiliations

  • 1 School of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang 330004, China; Formula-pattern Research Center, Jiangxi University of Chinese Medicine, Nanchang 330004, China; Nanchang Key Laboratory of Formula-Pattern Correspondence for Prevention and Treatment of Immune and Metabolic Diseases, Nanchang 330004, China.
  • 2 School of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang 330004, China; Formula-pattern Research Center, Jiangxi University of Chinese Medicine, Nanchang 330004, China.
  • 3 Faculty of Computer and Mathematical Sciences, Universiti Teknologi MARA, Shah Alam, Malaysia; School of Software, Nanchang University, Nanchang 330004, China.
  • 4 School of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang 330004, China.
  • 5 Laboratory Animal Science and Technology Center, Jiangxi University of Chinese Medicine, Nanchang 330004, China.
  • 6 School of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang 330004, China; Formula-pattern Research Center, Jiangxi University of Chinese Medicine, Nanchang 330004, China. Electronic address: [email protected].
  • 7 Formula-pattern Research Center, Jiangxi University of Chinese Medicine, Nanchang 330004, China; College of Nursing, Jiangxi University of Chinese Medicine, Nanchang 330004, China. Electronic address: [email protected].
Abstract

Gut microbiota dysbiosis and Th17/Treg cell imbalance play critical roles in the pathogenesis of ulcerative colitis (UC). Astragaloside IV (AS-IV) exhibits extensive anti-inflammatory and immunomodulatory activities; however, the crosstalk between gut microbiota and Th17/Treg cells modulated by AS-IV remains unreported. Here, chronic colitis was induced in mice by free access to 2.5 % dextran sulfate sodium (DSS) solution over three 7-day cycles, with concurrent AS-IV administration. AS-IV effectively alleviated DSS-induced chronic colitis in mice, as evidenced by increased body weight and colon length, decreased disease activity index (DAI), colon weight, colon weight/colon length, and colon weight index, and enhanced the gene and protein expression of tight junction molecules Claudin-1, Occludin, ZO-1. Notably, AS-IV not only effectively regulated the differentiation balance of Th17/Treg cells, but also significantly improved the composition of gut microbiota and butyric acid metabolism in chronic colitis mice. Intriguingly, Th17/Treg cells and butyric acid were significantly correlated with α/β diversity, as well as the genera Enterorhabdus, Mucispirillum, and Helicobacter. However, AS-IV lost its therapeutic efficacy against colitis and its regulatory effects on Th17/Treg cell balance and butyric acid metabolism following gut microbiota depletion. Critically, FMT from AS-IV-treated mice restored the protective effects against colitis and the regulation of Th17/Treg cell balance and butyric acid metabolism. Collectively, AS-IV inhibits chronic colitis by regulating gut microbiota composition, butyric acid metabolism, and Th17/Treg cell differentiation balance, whose protective effects are dependent on the regulatory mechanism of Th17/Treg cell differentiation balance mediated by gut microbiota-derived butyrate metabolism.

Keywords

Astragaloside IV; Chronic colitis; Fecal microbiota transplantation; Gut microbiota; Th17/Treg cells.

Figures
Products